Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR | P10275 | 5/20 | 0.44 |
| ▸ | CYP11B2 | P19099 | 3/20 | 0.42 |
| ▸ | MMP3 | P08254 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.39 |
| ▸ | KDM1A | O60341 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | NSD2 | O96028 | 1/20 | 0.37 |
| ▸ | KIF11 | P52732 | 1/20 | 0.37 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14525155 | 0.86 | AR (0.42) | ARCYP11B2MMP3ALDH1A1CYP2A6 | |
| SCHEMBL14525308 | 0.82 | AR (0.38) | ARCYP11B2MMP3KDM1ANSD2 | |
| SCHEMBL3997043 | 0.81 | MMP3 (0.46) | ARCYP11B2MMP3ALDH1A1CYP2A6 | |
| SCHEMBL8028511 | 0.80 | HRH2 (0.42) | ARCYP11B2 | |
| SCHEMBL17059023 | 0.78 | PTGER4 (0.37) | ARCYP11B2MMP3ALDH1A1KDM1A | |
| SCHEMBL8436238 | 0.77 | CYP2A6 (0.41) | ARALDH1A1CYP2A6 | |
| SCHEMBL410177 | 0.77 | CYP2A6 (0.41) | ARALDH1A1CYP2A6 | |
| SCHEMBL27784607 | 0.76 | KIF11 (0.43) | CYP11B2MMP3ALDH1A1CYP2A6NSD2 | |
| SCHEMBL25871771 | 0.76 | ALDH1A1 (0.48) | ARCYP11B2ALDH1A1CYP2A6 | |
| SCHEMBL23958923 | 0.75 | MAOB (0.43) | CYP11B2MMP3ALDH1A1CYP2A6KIF11 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070149570-A1 | Piperidine derivative and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2007-06-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070149570-A1 | Piperidine derivative and use thereof | TACR1, OPRL1, TRPV1 | AR 31/4885CYP11B2 1846/4885MMP3 1454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.